Conference Presentations, Posters & Abstracts
—
Past Pharsight®
Contributions
2007
December
Carrothers TJ. Concordance Between the Exposure-QTc Response Relationship in the Pooled Phase 1 Data vs. Thorough QTc Study. [invited presentation]. Presented at: 2nd Annual DIA Cardiac Safety Conference; December 3-4, 2007; Prague, Czech Republic. Reprinted courtesy of DIA, www.diahome.org.
November
Lukas JC. Modeling, Simulation and Meta-Analysis in Drug Development. [invited presentation]. Presented at: First National Meeting on Modeling and Simulation in Biomedicine, November 29-30, 2007; Valencia, Spain.
View Presentation Slides in Spanish
Dykstra K. Integrated Modeling and Simulation to Evaluate the Viability of a Proposed Drug Development Program. [invited presentation]. Presented at: AAPS Workshop on Quantitative Pharmacology: A Roadmap for Rational, Model-based Drug Development; November 10, 2007; AAPS Annual Meeting; San Diego, California.
Chittenden J.
In Vitro / In Vivo Correlation (IVIVC) Development for a model compound with release rate specific bioavailability. [poster abstract
T2037].
Presented at: AAPS Annual Meeting; November 11-15; San Diego, California.
Hovde M. Process Maturity of Model-Based Drug Development. [poster abstract W4544]. Presented at: AAPS Annual Meeting; November 11-15; San Diego, California.
Hodge L. Linking Modeling & Simulation, Decision Analysis, and the Technology of Drug Formulation. [invited presentation]. Presented at: INFORMS Annual Meeting 2007; November 4-7, 2007; Seattle, Washington.
October
Bruno R. Clinical Trial Simulations to Predict Efficacy and Survival Benefit of Anticancer Agents. [invited presentation]. International Symposium on Quantitative Pharmacology in Drug Development and Regulation; October 29, 2007; Nanjing, China.
Song S, Rohatagi S, Wickremasingha PK, Khariton T, Kshirsagar S, Carrothers T, Kuwabara-Wagg J. Model Based Dose Selection of a Quinolone to Minimize Drug Induced Serum Creatinine Elevation. [poster presentation]. Presented at: Annual Meeting of the American College of Clinical Pharmacy; October 14-17, 2007; Denver, Colorado.
Wickremasingha PK, Rohatagi S, Falcoz C, Kshirsagar S, Khariton T, Kastrissios H, Carrothers T, Kuwabara-Wagg J. Population Pharmacokinetics and Exposure-Response Modeling and Simulation to Support Quinolone Phase IIa Dose Selection. [poster presentation]. Presented at: Annual Meeting of the American College of Clinical Pharmacy; October 14-17, 2007; Denver, Colorado.
September
Testa B, Porzio S, Riva S, Fava L, Canali S, Falcoz C, Kshirsagar S. Population PK-PD modeling of a fully humanized monoclonal antibody in monkeys to guide the first time in man study. [poster presentation]. Presented at: Swedish Academy of Pharmaceutical Sciences Rosenon Meeting 2007; September 20-22, 2007; Stockholm, Sweden. Reprinted with permission of Merck-Serono.
Krause A, Pinheiro J. Modeling and Simulation to Adjust p-values in the Presence of a Regression to the Mean Effect. Presented at: ROeS Seminar (Austrian-Swiss Region of the International Biometric Society); Sepember 9-13, 2007; Bern, Switzerland.
Prins K. Modeling and Simulation Using Metadata: Away from Inventing the Wheel Again. Presented at: ROeS Seminar (Austrian-Swiss Region of the International Biometric Society); Sepember 9-13, 2007; Bern, Switzerland.
Rohatagi S, Song S, Sarapa N, Khariton T, Carrothers T, Kuwabara-Wagg J, Kastrissios H. Role of Modeling and Simulation in Evaluating the QTc Prolongation Potential of Drugs. [poster presentation]. Presented at: American College of Clinical Pharmacology (ACCP) 36th Annual Meeting; September 9-11, 2007; San Francisco, California.
Rohatagi S, Haworth SJ, Ezzet F, Kastrissios H. Model Based Development of a Direct Factor Xa Inhibitor. [poster presentation]. Presented at: American College of Clinical Pharmacology (ACCP) 36th Annual Meeting; September 9-11, 2007; San Francisco, California.
June
Bruno R. Model-based Predictions of Tumor Growth Dynamics in Clinical Oncology Studies. [invited presentation as part of post-conference short course]. Presented at: American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference; June 24-27, 2007; San Diego, California.
Cox EH, Prins NH, D'Souza G, McFadyen L. Integrated Modeling & Simulation of Clinical Response and Drop-out of D2 receptor agonists in Patients with Early Parkinson’s Disease. [presentation abstract 1221]. Presented at: Annual Meeting of the Population Approach Group in Europe (PAGE); June 13-15, 2007; Copenhagen, Denmark.
Dunlavey M. Next-Generation Modeling Language. Presented at: Annual Meeting of the Population Approach Group in Europe (PAGE); June 13-15, 2007; Copenhagen, Denmark.
Leary RH. An evolutonary nonparametric NLME algorithm. Presented at: Annual Meeting of the Population Approach Group in Europe (PAGE); June 13-15, 2007; Copenhagen, Denmark.
Prins NH, Graham G, Muto C, Pidgen A. Modeling of plasma aldosterone concentrations after prokinetic 5-HT4 receptor agonists: forming an integrated simulation framework for summary statistic and subject-level data. [poster abstract 1219]. Presented at: Annual Meeting of the Population Approach Group in Europe (PAGE); June 13-15, 2007; Copenhagen, Denmark.
Sheiner T. Planning to Communicate. Presented at: Annual Meeting of the Population Approach Group in Europe (PAGE); June 13-15, 2007; Copenhagen, Denmark.
Latz J, Claret L, Symanowski J, Falcoz C, Bruno R, Smith I, Calvert H. Evaluation of pemetrexed (PEM) dosing paradigms using exposure-response relationships (ERRs). [poster abstract 2530]. Presented at: 43rd ASCO Annual Meeting; June 1-5, 2007; Chicago, Illinois.
May
Dykstra K. Examining Clinical Utility: A New Formulation for an Old Drug. [invited presentation]. Presented at: 30th Annual Midwest Biopharmaceutical Statistics Workshop; May 21-23, 2007; Muncie, Indiana.
Rohatagi S, Carrothers T, Kshirsagar S, Khariton T, Lee J, Salazar D. Evaluation of Population (POP) Pharmacokinetics (PK) after Coadministration of Olmesartan Medoxomil (OM) and Amlodipine Besylate (AM), [poster P-429]. Presented at: Amercian Society of Hypertension 22nd Annual Scientific Meeting and Exposition; May 19-22, 2007; Chicago, Illinois.
April
Bruno R. Modeling of Cancer Progression and Drug Effects. [invited speaker abstract B24-3]. Presented at: Pharmaceutical Sciences World Congress (PSWC) 2007 Annual Meeting; April 22-25, 2007; Amsterdam, the Netherlands.
Hovde M. Modeling and Simulation: How Can We Make It More Impactful? [poster abstract P-476]. Presented at: Pharmaceutical Sciences World Congress (PSWC) 2007 Annual Meeting; April 22-25, 2007; Amsterdam, the Netherlands.
March
Mao ZL, Kastrissios H, Gao Y, Keirns J. POPULATION PHARMACOKINETIC ANALYSIS OF VERNAKALANT HYDROCHLORIDE INJECTION (RSD1235) FOR ATRIAL FIBRILLATION OR ATRIAL FLUTTER [poster PIII-100]. Presented at: Amercian Society for Clinical Pharmacology and Therapeutics (ASCPT) 2007 Annual Meeting; March 21-24, 2007; Anaheim, California.
January
Wagg J. Pharsight Perspective: Sharing Knowledge to Improve Clinical Development. Presented at: Drug Information Association Forum: Sharing Knowledge to Improve Clinical Drug Development and Regulatory Decisions: Data/models of Diseases, Drugs, Placebo, Baseline, and Dropouts; January 25, 2007; Washington, DC.